Loading
A phase 3 trial of Imlunestrant, Tamoxifen and Exemestane in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer is a phase 3 interventional study registered as NCT05514054 by Eli Lilly and Company, with 8000 participants enrolled, started 2022-10-04 and due to reach its primary completion in 2027-10. Interventions recorded: Imlunestrant, Tamoxifen, Anastrozole, Letrozole and Exemestane.
Shares Imlunestrant, Tamoxifen, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Exemestane, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tamoxifen, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.